DIA: Driving Insights to Action
Science:Life Sciences
On July 1 2018, Dr. Joseph Scheeren (Senior Advisor, R&D, Bayer) became Chair of the DIA Board of Directors. “In this time of great change, it is great to be part of an organization like DIA, which wants to bring stakeholders together in order to discuss and foster the development of new products and new technologies,” he explains. “We have a unique opportunity not only to bring these stakeholders together but also to serve as a platform for information for our members and even beyond our members.”
DIA: Going Beyond the Traditional Definition of Drug Development
GPP Experts Explain Authorship Algorithm
"Dossier in the Cloud" Democratizing Global Access
DIA: A Place Where You Can Make a Difference
Autumn’s Leukemia Story: Regimens, Recovery, and Realizations
Retiring TGA Head Maps Australia’s Post-Pandemic Future
Patient Engagement: Evolution of Who Knows What, Part 2
Patient Engagement: Evolution of Who Knows What, Part 1
Australian Clinical Trials Alliance Part 2 – Future Projections
ANVISA Explains Innovative Online Optimized Assessment Project
Australian Clinical Trials Alliance Part 1 – Current Perceptions
Looking Back and Ahead: Translational Science Advances Impacting Patient Care
Rwanda Welcomes African Medicines Agency Home
Will Technology Solve the Research “People Problem”?
Why Trans/Nonbinary Research Benefits All Communities
Digital Revolutionizing Data-Driven Reimbursement
China Sets New Record for Local Drug Approvals in 2021
WHO Pilot Formalizes CSA Process to Assist Developers
Medication Errors Emerge as Global Patient Safety Issue
What We Are Missing by Not Including ”Who?”
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology